VYLUMA TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Vyluma, a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it will participate in the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12, 2023 in San Francisco, Calif.
VYLUMA ANNOUNCES POSITIVE RESULTS FROM PHASE 3 CHAMP STUDY OF NVK002 FOR TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Preliminary data from landmark, three-year, international study demonstrate safety and efficacy of NVK002 as a potential treatment for the progression of myopia in children Bridgewater, NJ – October 27, 2022 – Vyluma, Inc (“Vyluma”), a biopharmaceutical...
VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia
VYLUMA AND LABORATOIRES THÉA ENTER INTO LICENSING AGREEMENT FOR THE REGISTRATION AND COMMERCIALIZATION OF NVK002 IN CANADA, MEXICO, AND SELECT SOUTH AMERICAN COUNTRIES
Bridgewater, NJ, USA, June 14, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an...
NEVAKAR INJECTABLES SELLS SIX DEVELOPMENT-STAGE, READY-TO-USE INJECTABLE PRODUCT CANDIDATES TO ENDO VENTURES LIMITED
Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced...
NEVAKAR INJECTABLES RECEIVES U.S. FDA APPROVAL OF READY-TO-USE EPHEDRINE INJECTION IN A PREFILLED SYRINGE
Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced...
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS
Bridgewater, NJ (October 7, 2021) – Vyluma Inc. and MyMyopiaTM (MyMyopia.com) are excited to announce new tools and resources to support the International Agency for the Prevention of Blindness (IAPB) World Sight Day, a global event to draw attention to blindness and...